Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BMN 333

Peptide · developed by BioMarin Pharmaceutical

Phase 2/3 Most advanced trial
BMRN Developer
1 Registered trials

What is BMN 333?

BMN 333 is a drug given as a weekly subcutaneous injection. They do not describe its molecular target or mechanism of action.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Therapy area
Musculoskeletal
Developer
BioMarin Pharmaceutical (BMRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07441876 Phase 2/3 Achondroplasia Recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Achondroplasia

More from BioMarin Pharmaceutical

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind BMN 333

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.